- Johnson & Johnson completed the acquisition of Halda Therapeutics for $3.05 billion.
- The acquisition includes the RIPTAC™ platform for targeted cancer therapies.
- HLD-0915, a prostate cancer therapy, is part of the acquisition.
- Earnings dilution of $0.20 per share is expected in 2025-2026.
Acquisition Details
Johnson & Johnson has completed its acquisition of Halda Therapeutics for $3.05 billion in cash. Halda is a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC™) platform.
Therapeutic Advancements
The acquisition includes HLD-0915, a clinical-stage therapy for prostate cancer, which is a once-daily oral treatment. This therapy uses the RIPTAC™ platform to target cancer cells and overcome resistance mechanisms.
Pipeline Expansion
Johnson & Johnson will also gain several early-stage candidates for breast, lung, and other tumor types, expanding its oncology portfolio. The RIPTAC™ technology may enable the development of targeted therapies beyond oncology.
Financial Impact
The acquisition will be accounted for as a business combination, with expected earnings dilution of approximately $0.20 per share in 2025 and 2026. This is due to non-recurring charges related to Halda employee equity awards, financing, and integration costs.
